Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Wednesday. $71.96 million flowed into the stock on the tick-up and $96.84 million flowed out of the stock on the tick-down, for a money net flow of $24.88 million out of the stock. Of all stocks tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.04 for the day and closed at $36.68

A number of research firms have recently issued reports on PFE. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.97 price objective on the stock. in a research report on Thursday, July 14th. Jefferies Group set a $41.50 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Thursday, July 14th. Piper Jaffray Cos. reissued an “overweight” rating and set a $54.00 price objective on shares of Pfizer in a research report on Monday, June 27th. Finally, Deutsche Bank AG reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, June 15th. Ten equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $38.11.

The company has a market capitalization of $222.46 billion and a PE ratio of 30.07. The firm’s 50-day moving average price is $35.30 and its 200-day moving average price is $32.33.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.55 by $0.12. The business had revenue of $13 billion for the quarter, compared to the consensus estimate of $12 billion. The company’s revenue was up 19.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.51 EPS. On average, analysts anticipate that Pfizer Inc. will post $2.45 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Investors of record on Friday, August 5th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 3.27%. The ex-dividend date is Wednesday, August 3rd.

In related news, CEO Ian C. Read sold 275,000 shares of the business’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $33.80, for a total transaction of $9,295,000.00. Following the sale, the chief executive officer now owns 1,446,738 shares of the company’s stock, valued at $48,899,744.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mikael Dolsten sold 67,588 shares of the business’s stock in a transaction dated Wednesday, May 4th. The stock was sold at an average price of $33.46, for a total transaction of $2,261,494.48. Following the sale, the insider now directly owns 438,107 shares in the company, valued at approximately $14,659,060.22. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. boosted its position in shares of Pfizer by 16.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 24,378,870 shares of the biopharmaceutical company’s stock valued at $786,951,000 after buying an additional 3,522,873 shares during the period. Longview Partners Guernsey LTD boosted its position in shares of Pfizer by 1.1% in the fourth quarter. Longview Partners Guernsey LTD now owns 20,115,395 shares of the biopharmaceutical company’s stock valued at $649,325,000 after buying an additional 220,284 shares during the period. Swiss National Bank boosted its position in shares of Pfizer by 1.4% in the fourth quarter. Swiss National Bank now owns 12,075,889 shares of the biopharmaceutical company’s stock valued at $389,810,000 after buying an additional 161,900 shares during the period. Jennison Associates LLC boosted its position in shares of Pfizer by 24.7% in the fourth quarter. Jennison Associates LLC now owns 11,912,098 shares of the biopharmaceutical company’s stock valued at $384,523,000 after buying an additional 2,361,977 shares during the period. Finally, California State Teachers Retirement System boosted its position in shares of Pfizer by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 11,774,052 shares of the biopharmaceutical company’s stock valued at $380,066,000 after buying an additional 186,091 shares during the period.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.